Biotechnology

Bio Green Med Solution

Bio Green Med Solution released FY2025 Q3 earnings on November 13, 2025 (EST), actual revenue USD 81 K (forecast USD 25 K), actual EPS USD -1.3087 (forecast USD -71.9999)

Bio Green Med Solution released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 81K and EPS of USD -2.93

Bio Green Med Solution released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 25K), actual EPS USD -1.5275 (forecast USD -71.9999)

Bio Green Med Solution released FY2024 Q2 earnings on August 14 After-Market EST, actual revenue USD 4K (forecast USD 15K), actual EPS USD 0 (forecast USD -344.3998)

Bio Green Med Solution released FY2024 Semi-Annual Earnings on August 14 After-Market EST, actual revenue USD 33 K, actual EPS USD 0

Bio Green Med Solution released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -1.62

Bio Green Med Solution released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 25 K), actual EPS USD -0.0937 (forecast USD -69.5999)

Bio Green Med Solution released FY2024 Q1 earnings on May 14 After-Market (EST), actual revenue USD 29K (forecast USD 0), actual EPS USD 0 (forecast USD -1.139K)

Bio Green Med Solution released FY2024 earnings on April 2, 2025 (EST), actual revenue USD 43K (forecast USD 53K), actual EPS USD -502.4648 (forecast USD -467.9997)

Bio Green Med Solution released FY2024 Q4 earnings on April 2, 2025 (EST), actual revenue USD 0 (forecast USD 10K), actual EPS USD -79.2521 (forecast USD -69.5999)

Bio Green Med Solution released FY2023 earnings on April 2 After-Market EST, actual revenue USD 420 K (forecast USD 389 K), actual EPS USD 0

Bio Green Med Solution released FY2023 Q4 earnings on April 2 After-Market EST, actual revenue USD 31K, actual EPS USD 0

Bio Green Med Solution released FY2024 9 Months Earnings on November 12 (EST), actual revenue USD 43K, actual EPS USD -43.7993

Bio Green Med Solution released FY2024 Q3 earnings on November 12 EST, actual revenue USD 10 K (forecast USD 10 K), actual EPS USD -43.7993 (forecast USD -129.5999)

Bio Green Med Solution released FY2023 Q3 earnings on November 12 After-Market EST, actual revenue USD 16 K, actual EPS USD 0

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap